Xencor Q4 2023 net loss $19.1M ($0.31 EPS); cash $697.4M; workforce cut ~10%

Xencor Inc

2023-FY EPS reported -$2.08 revenue$168,338,000

Q4 2023 revenue $44.7M vs $21.6M YoY; full-year net loss $126.1M ($2.08) vs $55.2M ($0.93) in 2022.
Cash and marketable securities $697.4M at Dec 31, 2023; guidance for end-2024 $475M-$525M, runway into 2027.
Vudalimab in high-risk mCRPC showed 33% ORR (4/12) and PSA90 in 25%; plans to advance or decide by H1 2025.
J&J milestones: $27.5M in Q4 2023; two new CD28 candidates selected; workforce cut ~10% in Jan 2024.
Pausing cytokine programs XmAb564 (IL2-Fc) and XmAb662 (IL12-Fc) after data review; dosing first patient for XmAb541 in H1 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Xencor Inc reported financial results for the fourth quarter and fiscal year ended December 31, 2023.

Period: the fourth quarter and fiscal year ended December 31, 2023
Result: reported results

Exact text from the filing

On February 27, 2024, Xencor, Inc. announced its financial results for the fourth quarter and fiscal year ended December 31, 2023 in the press release attached hereto as Exhibit 99.1 and incorporated herein by reference.

View on SEC.gov

Browse all earnings releases →

Xencor Inc filing history →

Source: SEC EDGAR

accession 0001326732-24-000002

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.